Cambrooke Therapeutics Introduces Tylactin RESTORE Powder for Tyrosinemia (TYR)

AYER, Mass.–(BUSINESS WIRE)–#RESTOREpowder–Cambrooke Therapeutics Inc., a leader in therapeutic nutrition for
inborn errors of metabolism and ketogenic diet therapy, announces the
launch of Tylactin™ RESTORE Powder, a medical food hydration
beverage, available in convenient portable single-serve stick-packs for
the dietary management of Tyrosinemia (TYR).

Tylactin with GMP is made from a natural whole protein derived from whey
called glycomacropeptide (GMP). Cambrooke Therapeutics was the first
company to provide individuals with Tyrosinemia natural whole protein
medical foods—Tylactin RTD and Tylactin RESTORE. Now, Tylactin
RESTORE Powder provides an additional option for individuals
struggling to consume their formula or those people who need a compact,
easy-to-mix, and great-tasting formula.

Tylactin RESTORE Powder contains 5g protein equivalents (PE). The
formulation is a great option for those with an active lifestyle as it
helps to replenish electrolytes lost during activities. Tylactin
RESTORE Powder comes in an all-natural, great-tasting orange flavor.
The stick-pack shape of the Tylactin RESTORE Powder packets makes
them easy to mix into a bottle of water or an on-the-go sports bottle. Tylactin
RESTORE Powder is an ideal addition to any TYR diet program for use
at school, during sports or any time on-the-go convenience is desired.

“The formula options are so limited for the Tyrosinemia community. I
continually struggled to take my formula,” says Michael D., a teenager
with TYR. “I never really liked my formula, but I had to take it because
there was nothing else available. With the Tylactin products, I not only
have a great tasting product, but it’s so convenient to take. I actually
look forward to drinking my formula.”

About Cambrooke Therapeutics – Founded in 2000, Cambrooke
Therapeutics is a private equity-backed, Massachusetts-based therapeutic
nutrition company and global provider of medical nutrition products for
patients with serious unmet medical needs. The company works with
physicians and researchers from around the world to develop, test and
commercialize products that are focused on inborn errors of metabolism
and intractable epilepsy. More information is available at www.cambrooketherapeutics.com.

Contacts

Cambrooke Therapeutics Inc.
Elayna Rucker-Byers, 301-980-6594
erucker-byers@cambrooke.com